Non-small-cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancer cases. For patients with early-stage disease, surgery followed by adjuvant chemotherapy is the optimal treatment. For patients with locally advanced disease, the standard approach is chemoradiotherapy, since it offers a small but statistically significant prolongation in survival compared with the sequential approach. It should be noted, however, that this approach is associated with significant toxicity and it only applies to patients with good performance status. For patients with metastatic disease, chemotherapy represents the cornerstone of treatment and results in a median survival of approximately 10 months. Recently, the addition of bevacizumab or cetuximab to chemotherapy doublets and the use of gefitinib and erlotinib has improved the outcome in selected patients with advanced NSCLC. Hopefully, advances in understanding the molecular biology of cancer and mechanisms of tumourigenesis will facilitate the discovery and development of novel 'targeted agents' and will further improve outcomes for these patients.
be achieved with lobectomy, sleeve lobectomy is recommended over pneumonectomy because it preserves pulmonary function. 12 
Definitive Radiotherapy
Although surgery is the treatment of choice for NSCLC patients with early-stage disease, some never undergo surgery. Common reasons for not undergoing surgery are older age, the presence of serious co-morbidities and patient refusal. For those patients who do not undergo an operation, radiotherapy can be administered with curative intent, albeit with lower survival rates when compared to surgery. 15, 16 
Adjuvant Chemotherapy
Recent data from randomised adjuvant clinical trials 17, 18 and a recent meta-analysis 19 have changed the standard of care for patients with completely resected NSCLC. The survival benefit observed with adjuvant chemotherapy was confirmed by a meta-analysis of five randomised trials 17, 18, [20] [21] [22] with 4,584 patients registered in the Lung Adjuvant Cisplatin Evaluation database. 19 This meta-analysis IA disease appeared to do worse with adjuvant chemotherapy. Some retrospective data suggest that patients with stage IB disease and tumours ≥4 cm may also benefit from adjuvant chemotherapy. 23 A more recent meta-analysis based on individual patient data confirmed the survival benefit in favour of adjuvant chemotherapy. 24 This benefit was irrespective of whether chemotherapy was adjuvant to surgery alone or adjuvant to surgery plus radiotherapy.
Adjuvant Radiotherapy after Surgical Resection
The post-operative radiotherapy (PORT) meta-analysis, 25,26 which included 2,128 patients, demonstrated that the use of post-operative radiotherapy was associated with a detrimental effect on survival, which was more pronounced for patients with lower nodal status.
The PORT meta-analysis has been criticised, however, for its long enrolment period and use of different types of machines, techniques and doses.
Three randomised phase III trials published subsequent to the PORT meta-analysis failed to support a benefit for the use of post-operative radiotherapy. [27] [28] [29] For patients with N2-positive disease, however, a retrospective analysis demonstrated higher survival for those patients who had received post-operative radiotherapy. 18 On the basis of these results, routine post-operative radiotherapy is not recommended for patients with completely resected stage I-IIIA NSCLC. 44 This was the first trial clearly demonstrating a significant 
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Targeted Therapies in First-line Treatment
Bevacizumab Angiogenesis, the formation of new blood vessels, is a fundamental process for the development of solid tumours and the growth of secondary metastatic lesions. 45 Vascular endothelial growth factor (VEGF) acts to promote normal and tumour angiogenesis. 46 Bevacizumab is a recombinant, humanised, monoclonal antibody against VEGF. 47 Two Phase III trials have evaluated the role of bevacizumab in combination with chemotherapy as first-line treatment (see Table 1 ). 49 The AVAiL trial did not demonstrate an OS benefit, but it should be underlined that its primary end-point was PFS and the study
was not powered to demonstrate an OS difference. In these trials bevacizumab was continued until disease progression. Two large Phase IV studies (the Safety of avastin in lung cancer study 50 48 yielded positive results for both doses tested (7.5 and 15 mg/kg). It should be noted that due to the significant risk of haemorrhage, a number of patients were excluded from bevacizumab trials. These patients had:
• squamous histology;
• history of haemoptysis (more than half a teaspoon of bright red blood per event);
• central nervous system metastases;
• history of thrombotic or haemorrhagic disorders;
• therapeutic anticoagulation;
• patients with tumours invading or abutting major blood vessels;
• clinically significant cardiovascular disease; or
• medically uncontrolled hypertension.
Thus, bevacizumab is recommended in combination with chemotherapy as first-line treatment in patients with certain clinical characteristics.
Cetuximab
Epidermal growth factor receptor (EGFR) is a transmembrane receptor that is highly expressed in NSCLC. 52 Binding of ligands (epidermal growth factor, tumour growth factor-alpha, betacellulin, epiregulin and amphiregullin) to the extracellular EGFR domain results in autophosphorylation through tyrosine kinase activity. 53 This initiates an intracellular signal transduction cascade that affects cell proliferation, motility and survival. 52 Monoclonal antibodies compete with ligands to bind with the extracellular part of the EGFR. When ligand and EGFR interaction is inhibited, the EGFR dependent on the downstream pathway cannot be triggered (when not permanently activated by a mutation event). Two prospective, randomised Phase III trials evaluated the combination of cetuximab and chemotherapy doublets (see Table 2 ). The first compared a cisplatin/vinorelbine plus or minus Lung Cancer Table 3 ).
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The first of these trials, the Iressa Pan-Asia Study ( 64 This trial demonstrated a striking PFS difference in favour of erlotinib with a median PFS for erlotinib versus chemotherapy of 13.1 months versus 4.6 months, respectively (see Table 3 ). These data support the first-line use of EGFR tyrosine kinase inhibitors for patients with activating EGFR mutations. If EGFR mutation status is negative or unknown, then cytotoxic chemotherapy is preferred. 
Second-line Treatment
Docetaxel has received approval as a second-line treatment on the basis of the results of a randomised Phase III trial that demonstrated a time-to-tumour-progression and an OS prolongation over placebo. 70 This study established docetaxel as the standard comparator arm for subsequent randomised trials. A more recent, non-inferiority Phase III study compared docetaxel with pemetrexed as second-line therapy in NSCLC. 71 No significant difference was observed in OS or one-year survival, while pemetrexed was associated with a more favourable toxicity profile. This trial led to the approval of pemeterexed for the second-line treatment of NSCLC. 
Targeted Agents
Conclusion
The addition of bevacizumab to chemotherapy doublets and the use of gefitinib and erlotinib has improved the outcome in selected patients with advanced NSCLC. Hopefully, advances in understanding the molecular biology of cancer and mechanisms of tumourigenesis will facilitate the discovery and development of novel 'targeted agents' and will further improve outcomes for these patients. n A Review of Treatment in Non-small-cell Lung Cancer
